CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $1.98M, lower than 95% of all stocks globally
- PositionGross margin is 100%, higher than 95% of its Biotechnology peers (median 77.2%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.04TKRW1.47B · vs all stocks (USD)
Revenue (TTM)
2.75BKRW1.98M · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.63xvs all stocks
52-Week Change
-79.30%vs all stocks
Market Capitalization
2.04TKRW1.47B · vs all stocks (USD)
Enterprise Value
1.96TKRW1.41B · vs all stocks (USD)
Price to Book (MRQ)
14.71xvs Biotechnology peers
Enterprise to Revenue
713.08xvs Biotechnology peers
Enterprise to EBITDA
-61.37xvs Biotechnology peers
Gross Margin
100.00%vs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1492.30%vs Biotechnology peers
Return on Assets (TTM)
-11.25%vs Biotechnology peers
Return on Equity (TTM)
-20.48%vs Biotechnology peers
Revenue (TTM)
2.75BKRW1.98M · vs all stocks (USD)
Revenue per Share (TTM)
63.00KRWUpdated Sep 21, 2026Quarterly Revenue Growth
-28.40%vs Biotechnology peers
Gross Profit (TTM)
2.73BKRW1.97M · vs all stocks (USD)
EBITDA (TTM)
-31.96BKRW-23.05M · vs all stocks (USD)
Net Income (TTM)
-21.60BKRW-15.58M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-28.39%vs Biotechnology peers
Operating Cash Flow (TTM)
-24.89BKRW-17.96M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-40.23BKRW-29.02M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-514.69MKRWFY2025 · Dec 31, 2025Revenue
4.30BKRWFY2025 · Dec 31, 2025Gross Profit
4.30BKRWFY2025 · Dec 31, 2025Operating Income
-33.99BKRW-24.52M · vs all stocks (USD)
Pre-tax Income
-24.90BKRWFY2025 · Dec 31, 2025Income Tax Expense
-921.61MKRWFY2025 · Dec 31, 2025Net Income
-23.98BKRWFY2025 · Dec 31, 2025EBIT
-24.43BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-29.25BKRWFY2025 · Dec 31, 2025Research & Development
25.05BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
2.39BKRWFY2025 · Dec 31, 2025Other Operating Expenses
834.59MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
861.83MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
470.60MKRWFY2025 · Dec 31, 2025EPS (Basic)
-547.00KRWFY2025 · Dec 31, 2025EPS (Diluted)
-772.00KRWFY2025 · Dec 31, 2025Basic Shares Outstanding
43.06MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
43.06MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-24.90BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
425.10MKRWFY2025 · Dec 31, 2025Operating Cash Flow
-21.90BKRWFY2025 · Dec 31, 2025Free Cash Flow
-21.96BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
32.88BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-24.90BKRWFY2025 · Dec 31, 2025Stock-based Compensation
1.47BKRWFY2025 · Dec 31, 2025Other Non-cash Items
-391.23MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
3.99BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.06BKRWFY2025 · Dec 31, 2025Capital Expenditures
-64.41MKRWFY2025 · Dec 31, 2025Other Investing Activity
-25.84MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-90.25MKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-925.12MKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-925.12MKRWFY2025 · Dec 31, 2025Other Financing Charges
19.58BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
25.11BKRWFY2025 · Dec 31, 2025Shares Outstanding
43.80MSharesUpdated Sep 21, 2026Float Shares
32.92MSharesUpdated Sep 21, 2026% Held by Insiders
20.13%vs all stocks
% Held by Institutions
10.21%vs all stocks
Total Cash (MRQ)
152.26BKRW109.83M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.45KKRWUpdated Sep 21, 2026Total Debt (MRQ)
115.09BKRW83.02M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.8583xvs Biotechnology peers
Current Ratio (MRQ)
27.21xvs Biotechnology peers
Book Value per Share (MRQ)
3.03KKRWUpdated Sep 21, 2026Total Assets
97.54BKRW70.36M · vs all stocks (USD)
Total Current Assets
50.99BKRWFY2025 · Dec 31, 2025Total Liabilities
18.56BKRWFY2025 · Dec 31, 2025Total Non-current Assets
46.55BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
13.14BKRWFY2025 · Dec 31, 2025Total Current Liabilities
5.42BKRWFY2025 · Dec 31, 2025Cash Equivalents
32.88BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
32.88BKRWFY2025 · Dec 31, 2025Other Short-term Investments
200.00KRWFY2025 · Dec 31, 2025Short-term Debt
1.98BKRWFY2025 · Dec 31, 2025Other Current Liabilities
40.00KRWFY2025 · Dec 31, 2025Long-term Debt
4.27BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
480.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
21.77BKRWFY2025 · Dec 31, 2025Retained Earnings
-332.92BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
78.98BKRW56.97M · vs all stocks (USD)
52-Week Low
44.00KKRWUpdated Sep 21, 202652-Week High
342.50KKRWUpdated Sep 21, 202652-Week Change
-79.30%vs all stocks
Beta
1.63xvs all stocks
50-Day MA
57.30KKRWUpdated Sep 21, 2026200-Day MA
77.82KKRWUpdated Sep 21, 2026Avg 10-Day Volume
462.70KSharesUpdated Sep 21, 2026Avg 30-Day Volume
800.42KSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-772.00KRWUpdated Sep 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 100%, higher than 95% of its Biotechnology peers (median 77.2%)Significant
Gross margin: 1.00Industry median: 0.77Industry P95: 0.99Peers compared: 193
Current ratio is 27.21×, higher than 95% of its Biotechnology peers (median 5.28×)Significant
Current ratio: 27.21Industry median: 5.28Industry P95: 22.31Peers compared: 193
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 1.00Profit Margin: 0.00
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $1.98M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,983,938.471Global P5: 33,357,653.812
Market cap is $1.47B, above the global median of $1.18BNotable
Market cap (USD): 1,474,635,851.925Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Concord Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Classys Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Taienkang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inhibrx Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Mayinglong Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Omeros Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tyra Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Balance Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Maze Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Goodluck India Ltd.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
The Italian Sea Group S.p.A.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
India Glycols Ltd.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated